Skip to main content

Health and Medicine

Triple-negative breast cancer drug therapy shows promise

Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

Read more


Loss of ‘Jedi’ alters neuron activity

Mar. 10, 2020—This is not the Jedi you're thinking of. This Jedi is a receptor that helps clear away dead neurons during development, and its loss changes the activity of dorsal root ganglia neurons, which could have implications for treating chronic pain.

Read more


Clues to lung injury in preterm babies

Mar. 5, 2020—Jennifer Sucre and colleagues have discovered a factor that contributes to the pathological changes of bronchopulmonary dysplasia, the most common complication of preterm birth.

Read more


One-two punch for cancer

Mar. 5, 2020—A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.

Read more


Study finds certain genetic test not useful in predicting heart disease risk

Feb. 27, 2020—A Polygenic Risk Score — a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients — has been found not to be a useful predictive biomarker for disease risk.

Read more


Breast cancer study may help predict treatment response

Feb. 27, 2020—Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

Read more


Grant bolsters research on subjective cognitive decline

Feb. 27, 2020—Katherine Gifford, PsyD, MS, assistant professor of Neurology, has been awarded a five-year, $4.3 million research grant from the National Institute on Aging to study what subjective cognitive decline can reveal about underlying pathology.

Read more


Potential new heartburn drug studied at VUMC

Feb. 26, 2020—An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.

Read more


Looking through MudPIT for protein interactions

Feb. 25, 2020—The identification of novel protein interactions and sites of modification in proteins involved in mRNA translation adds to understanding of a process that is an important therapeutic target.

Read more


Reducing postoperative opioids

Feb. 24, 2020—An opioid-restrictive prescribing protocol reduced the number of postoperative opioid prescriptions and the oral morphine equivalent per prescription.

Read more


Protein interactions and brain function

Feb. 20, 2020—Roger Colbran and colleagues have discovered new molecular details about the function of an enzyme with a key role in shaping learning and memory.

Read more


Post-transplant diabetes may be reversible: study

Feb. 20, 2020—Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.

Read more


VIEW MORE EVENTS >